Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) Published. Apr 18, 2019 4:05pm EDT. LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn ...

LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug ...

Employees were blindsided by Akorn's shutdown, they said Friday at a rally outside the Amityville plant, where the company made generic drugs, including the anesthetic lidocaine and fluticasone ...

Shares of Akorn (NASDAQ: AKRX) jumped over 14% on Monday after the company announced multiple regulatory approvals. The specialty generic-pharmaceutical leader said Abbreviated New Drug ...

Akorn is paying $43.50 a share for Hi-Tech, or 24 percent more than Hi-Tech's closing price on Monday. Shares in both companies soared Tuesday after the purchase announcement. Hi-Tech closed up $7 ...

Akorn said the FDA greenlighted two of its generic candidates: 1) fluticasone propionate nasal spray USP, 50 mcg per spray and 2) loteprednol etabonate ophthalmic suspension, 0.5 percent ...

Akorn Inc.'s CEO stepped down after the Delaware Supreme Court ruled that a rapid downturn in its business was grounds for Fresenius SE to walk away from a $4.3 billion buyout of the generic drug ...

Fierce Pharma reported that Akorn also filed for Chapter 11 bankruptcy in 2020, and was in acquisition talks in 2018for $4.3 billion with Fresenius, a German drug maker, but Fresenius pulled back ...

Fluticasone is a type of corticosteroid that can treat issues such as allergies and asthma. It is available in various forms, including an ointment, nasal spray, and inhaled medication.

There are many potential side effects from fluticasone, depending on the type you’re taking. We explore forms, precautions, and more if you’re taking fluticasone.

This finding was consistent with the results of previous trials and meta-analyses of fluticasone–salmeterol, 9,10,18 which showed no greater risk of serious asthma-related events among patients ...

Generic-drug maker Akorn has run into accounting issues. In today’s frenzied deal market, though, that might attract interest.